Product Name: | Chicken Vascular Endothelial cell Growth Factor A(VEGF-A) ELISA KIT |
Product Type : | ELISA Kit |
Code : | PDT02978E |
Size : | 96T,5×96T,10×96T |
Uniprot NO. : | P67964 |
Abbreviation : | VEGFA |
Protein Biological Process 1 : | Angiogenesis |
Alias : | RP1-261G23.1, MGC70609, MVCD1, VEGF, VEGF-A, VPF, vascular endothelial growth factor isoform VEGF165|vascular permeability factor |
Species : | Chicken |
Protein Biological Process 3 : | Angiogenesis |
Sample Types : | serum, plasma, tissue homogenates |
Detect Range : | 15.6 pg/ml-1000 pg/ml |
Sensitivity : | 3.9 pg/ml |
Assay Time : | 1-5h |
Sample Volume : | 50-100ul |
Detection Wavelengt : | 450 nm |
Availability : | 3-5 working days |
Research Area : | Cancer |
Protocol : | Protocol may be improved. Please feel free to contact us to obtain the latest version. |
Target details : | This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. |
Precision : | Intra-assay Precision (Precision within an assay): CV%<8% |
|
|
| Three samples of known concentration were tested twenty times on one plate to assess. |
| Inter-assay Precision (Precision between assays): CV%<10% |
|
|
| Three samples of known concentration were tested in twenty assays to assess. |
|
|
|
|
|
|
|
|
|
|
Linearity : | To assess the linearity of the assay, samples were spiked with high concentrations of chicken VEGF-A in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. |
| Sample | Serum(n=4) |
| 1:1 | Average % | 92 |
| Range % | 89-108 |
| 1:2 | Average % | 89 |
| Range % | 82-96 |
| 1:4 | Average % | 95 |
| Range % | 90-104 |
| 1:8 | Average % | 95 |
| Range % | 86-98 |
|
|
Recovery : | The recovery of chicken VEGF-A spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | |
Sample Type | Average % Recovery | Range |
| Serum (n=5) | 93 | 89-100 |
| EDTA plasma (n=4) | 95 | 89-101 |
|
|
|
|
|
|
|
|
|